ArticleClinical epigenetics2026
The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality in cigarette smokers: the Multiethnic Cohort study.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of smoking behaviors with GOLD biological age acceleration and potential mediation: Evidence from NHANES 1999-2023.Tobacco induced diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAmong cigarette smokers, higher internal smoking dose is associated with elevated lung cancer risk and mortality, independent of smoking pack-years. Some measures of epigenetic age acceleration (EAA) are associated with cigarette smoking status and exposure, as well as lung cancer risk and overall mortality. No study has examined the association between EAA measures and internal smoking dose (total nicotine equivalents (TNE; nmol/mL)), and their shared relationship with lung cancer incidence and mortality in a multiethnic population.
methodsFrom a subgroup of Multiethnic Cohort Study participants who smoked cigarettes at the time of biospecimen collection (n = 1969), six epigenetic clocks were computed using blood-based DNA methylation (DNAm) array data. EAA measures were computed by calculating the residuals that results from regressing an epigenetic clock on chronological age. The association of urinary TNE with EAA measures were assessed using linear regression models, adjusted for age, sex, body mass index (BMI; kg/m
resultsA standard deviation (SD) increase of log-TNE was statistically significantly associated with increased AgeAccelPheno (beta = 0.416, 95% Confidence Interval (CI)=0.134-0.698)), AgeAccelGrim (beta = 0.771, 95%CI=0.603-0.939), and DunedinPACE (beta = 0.015, 95%CI=0.010-0.020). A SD increase of AgeAccelGrim (Hazard Ratio (HR) = 1.40; 95% CI 1.16-1.71) and DunedinPACE (HR = 1.31; 95% CI 1.11-1.55) were associated with a risk of lung cancer, whereas a SD increase of AgeAccelDNAm-based telomere length was inversely associated with lung cancer risk (HR = 0.79; 95% CI 0.67-0.93). These findings were similar for the hazard of all-cause mortality.
conclusionsOur study suggests that circulating methylation-based biomarkers of biological aging may provide information on lung cancer risk and all-cause mortality beyond that of self-reported pack-years and a (short-term) biomarker of internal smoking dose. If replicated, our findings suggest that epigenetic clocks may inform higher risk groups for prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.